Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY 4.0Infection

Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody

  • Koh Shinohara1,2
  • Kentaro Tochitani3
  • Yoshiki Katada2,4
  • Tatsunori Murata5
  • Mayu Morita5
  • Yusuke Tsuda1,2
  • Yasuhiro Tsuchido1,2
  • Masaki Yamamoto1,2
  • Yasufumi Matsumura1,2
  • Miki Nagao1,2
5 affiliations
  1. 1Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan
  2. 2Department of Infection Control and Prevention, Kyoto University Hospital, 54 Shogoin- Kawahara-cho, Sakyo-ku, Kyoto, Japan
  3. 3Department of Infectious Diseases, Kyoto City Hospital, 1-2 Mibu-Higashi-Takada-cho, Nakagyo-ku, Kyoto, Japan
  4. 4Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan
  5. 5Department of Pharmacy, Kyoto City Hospital, 1-2 Mibu-Higashi-Takada-cho, Nakagyo- ku, Kyoto, Japan
Read full textPDFDOICite

Abstract

Purpose: Although indications for anti-interleukin 6 (IL-6) receptor antibody (anti-IL6R) therapy continue to expand, the clinical features of bloodstream infection (BSI) in anti-IL6R recipients remain poorly characterized. We investigated the prevalence, clinical and microbiological features of BSI among the anti-IL6R recipients.

Methods: We conducted a multicenter, retrospective study of BSI episodes occurring within 90 days of anti-IL6R administration between 2005 and 2024. Complicated BSI was defined as the presence of either (1) infection-related mortality, (2) remote or localized suppurative complications, (3) embolic stroke, or (4) recurrence within 90 days. Associations between clinical variables and complicated BSI were analyzed.

Results: Among 922 anti-IL6R recipients, 47 patients (5%) developed BSI. Demographics varied by indication for anti-IL6R, and 89% received concomitant immunosuppressive therapy. Catheter-related bloodstream (23%) and intra-abdominal (21%) were most common foci, followed by bone and joint (14%). At presentation, fever was absent in 53%, and serum CRP was within normal range in 30%. Septic shock occurred in 26%, and all-cause 30-day mortality was 19%. Complicated BSI occurred in 22 episodes (47%). In univariate analysis, underlying rheumatic disease, community acquisition, onset within 21 days of anti-IL6R administration, and Staphylococcus aureus or Klebsiella pneumoniae etiology were associated with complicated BSI, whereas higher pulse rate at presentation and Pitt bacteremia score ≥ 4 were inversely associated.

Conclusions: In anti-IL6R recipients, BSI frequently lacked typical signs such as fever but often resulted in severe outcomes. Clinicians should maintain a high index of suspicion for complicated BSI in this population.

Related

  1. A Descriptive Observational Study of Real-Time TDM-Guided Aggressive PK/PD Target Attainment and Microbiological/Clinical Outcome in Patients with Stenotrophomonas maltophilia Bloodstream Infections and/or Pneumonia Treated with Continuous Infusion Cefiderocol.
    Milo Gatti, Matteo Rinaldi, Simone Ambretti +3
    Antibiotics (Basel, Switzerland)Peer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  2. Use of a molecular syndromic panel for the etiological diagnosis of bloodstream infections in critically ill patients: impact on clinical outcomes and antimicrobial use from a multicenter, prospective study.
    Daniele Roberto Giacobbe, Claudia Bartalucci, Greta Cattardico +60
    Annals of medicinePeer-reviewedCC BYFull textInfectious diseaseEurope PMCPMC
  3. Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
    Cihan Yeşil, Cemile Arslan Yeşil, Ferhat Yılmaz +2
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Clinical characteristics and prognosis of liver injury in patients receiving immune checkpoint inhibitor-based therapy: a real-world retrospective study
    Liang Gao, Xiaotian Yang, Fengkun Yang +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  5. [Clinical characteristics and in-hospital outcomes of patients receiving antithrombotic therapy in a cardiac intensive care unit in sub-Saharan Africa: a retrospective comparative study at the Cardiology Institute of Abidjan].
    Christelle Gbassi, Florent Koffi, Cédric Kee +10
    The Pan African medical journalPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{shinohara2026clinical,
  title = {{Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody}},
  author = {Koh Shinohara and Kentaro Tochitani and Yoshiki Katada and Tatsunori Murata and Mayu Morita and Yusuke Tsuda and Yasuhiro Tsuchido and Masaki Yamamoto and Yasufumi Matsumura and Miki Nagao},
  journal = {Infection},
  year = {2026},
  month = aug,
  doi = {10.1007/s15010-026-02938-0},
  url = {https://doi.org/10.1007/s15010-026-02938-0},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody
AU  - Koh Shinohara
AU  - Kentaro Tochitani
AU  - Yoshiki Katada
AU  - Tatsunori Murata
AU  - Mayu Morita
AU  - Yusuke Tsuda
AU  - Yasuhiro Tsuchido
AU  - Masaki Yamamoto
AU  - Yasufumi Matsumura
AU  - Miki Nagao
PY  - 2026
DA  - 2026/08/18
JO  - Infection
DO  - 10.1007/s15010-026-02938-0
UR  - https://doi.org/10.1007/s15010-026-02938-0
AB  - Purpose: Although indications for anti-interleukin 6 (IL-6) receptor antibody (anti-IL6R) therapy continue to expand, the clinical features of bloodstream infection (BSI) in anti-IL6R recipients remain poorly characterized. We investigated the prevalence, clinical and microbiological features of BSI among the anti-IL6R recipients.  Methods: We conducted a multicenter, retrospective study of BSI episodes occurring within 90 days of anti-IL6R administration between 2005 and 2024. Complicated BSI was defined as the presence of either (1) infection-related mortality, (2) remote or localized suppurative complications, (3) embolic stroke, or (4) recurrence within 90 days. Associations between clinical variables and complicated BSI were analyzed.  Results: Among 922 anti-IL6R recipients, 47 patients (5%) developed BSI. Demographics varied by indication for anti-IL6R, and 89% received concomitant immunosuppressive therapy. Catheter-related bloodstream (23%) and intra-abdominal (21%) were most common foci, followed by bone and joint (14%). At presentation, fever was absent in 53%, and serum CRP was within normal range in 30%. Septic shock occurred in 26%, and all-cause 30-day mortality was 19%. Complicated BSI occurred in 22 episodes (47%). In univariate analysis, underlying rheumatic disease, community acquisition, onset within 21 days of anti-IL6R administration, and Staphylococcus aureus or Klebsiella pneumoniae etiology were associated with complicated BSI, whereas higher pulse rate at presentation and Pitt bacteremia score ≥ 4 were inversely associated.  Conclusions: In anti-IL6R recipients, BSI frequently lacked typical signs such as fever but often resulted in severe outcomes. Clinicians should maintain a high index of suspicion for complicated BSI in this population.
SN  - 0300-8126
SN  - 1439-0973
ER  -